Nanalysis Scientific Corp. reports developments tied to portable Nuclear Magnetic Resonance spectrometers, MRI and imaging technology, and related services for industrial and research applications. Company updates describe instruments used in pharmaceutical, biotech, energy, food, materials, security, academic, and government settings, as well as a services division that maintains Nanalysis products and third-party imaging equipment.
Recurring news themes include quarterly and annual results, conference-call announcements, supply-chain and market-diversification updates, non-dilutive funding, private placement financings, equity incentive grants, and board composition changes. The company also references its long-term Canadian Air Transport Security Authority relationship for security-scanner maintenance at Canadian airports.
Nanalysis Scientific Corp. (OTCQX: NSCIF), a leader in portable NMR instruments and imaging technology, has scheduled its Q2 2025 earnings conference call for August 28th, 2025 at 5:00 PM ET. CEO Sean Krakiwsky and CFO Randall McRae will host the call to discuss results for the quarter ended June 30, 2025.
Investors can participate by dialing 1-437-900-0527 or 1-888-510-2154 from abroad, or access the webcast through the company's investor relations website. A separate European Q&A session will be held on August 29th at 8:30 AM ET. The webcast will be archived for 90 days, and a playback will be available for seven days.
Nanalysis Scientific Corp. (OTCQX: NSCIF) has achieved a significant milestone with the first regulatory certified assay for benchtop Nuclear Magnetic Resonance (NMR) being accepted by the United States Pharmacopeia (USP) and European Pharmacopeia. The certified method is for Molar Substitution Determination in Hydroxypropyl Betadex, an important excipient used in various pharmaceutical products.
This breakthrough enables the use of 60 MHz benchtop NMR for pharmaceutical quality control, marking a shift from traditional expensive and complex superconducting high-field NMR technology. The company is actively developing additional formal methods for ASTM, AOAC, and ISO standards, positioning benchtop NMR for widespread industrial adoption.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) has scheduled its First Quarter 2025 earnings conference call for Wednesday, May 28th, 2025, at 5:00 PM ET. CEO Sean Krakiwsky and CFO Randall McRae will discuss the financial results for the quarter ended March 31, 2025. Investors can participate by dialing 1-888-510-2154 (domestic) or 437-900-0527 (international), or via webcast.
A dedicated European Q&A session will follow on Thursday, May 29th at 8:30 AM ET. The earnings call webcast will be archived for 90 days on the company's website, and a telephonic replay will be available for seven days using conference ID #00805.
Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) reported strong financial results for Q4 and full year 2024. The company achieved record quarterly revenue of $12.3 million (25% YoY growth) and record annual revenue of $45 million (60% YoY growth).
Key financial highlights include:
- Q4 Adjusted EBITDA of $1.8M vs -$677K in Q4 2023
- Annual Adjusted EBITDA of $2.8M vs -$7.9M in 2023
- Product sales gross margin improved to 53% from 41% YoY
- Security services revenue grew 121% to $21M
- Positive operating cash flow of $3.3M for 2024
The company noted potential headwinds from U.S. tariffs affecting product sales in H1 2025, though mitigation efforts are in place. Management remains focused on expanding margins, growing Benchtop NMR sales, and optimizing their service business.
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) has scheduled its Fourth Quarter and Full Year 2024 earnings conference call for Thursday, April 24th, 2025, at 5:00 PM Eastern Time. The company will release its financial results via press release on the same day.
CEO Sean Krakiwsky and CFO Randall McRae will host the conference call. Investors can participate through:
- Dial-in numbers: 1-888-510-2154 (domestic) or 437-900-0527 (international)
- Online webcast: Available through the company's investor relations website
- Playback: Available for 7 days via phone (1-888-660-6345 or 289-819-1450, Conference ID: 87924)
Additionally, a separate Q&A session for European investors is scheduled for Friday, April 25th, 2025, at 8:30 AM ET.
Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) has announced the release of new automation software aimed at simplifying NMR spectroscopy for industrial applications. The qNMR module is designed to automate routine qNMR assays, making it easier for technicians to collect data without requiring expertise in NMR spectroscopy.
The software is compatible with both the company's 100 MHz and 60 MHz products, and works with autosamplers for increased throughput. This development addresses a key challenge in implementing NMR technology in quality control and quality assurance environments, where traditional NMR instrumentation has been impractical.
The company has implemented a four-pronged strategy to expand its benchtop NMR platforms in industrial QA/QC:
- Identifying and validating methods with strong ROI
- Ensuring data integrity requirements
- Exploring regulation compliance
- Reducing expertise barriers
Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) has launched its next-generation 60 MHz Benchtop NMR spectrometer at the Pittcon Conference and Expo in Boston. The new Nanalysis-60 represents a significant upgrade from the previous model, featuring:
- Enhanced power and sensitivity for analyzing small compound amounts
- Improved accuracy and resolution for better compound quantification
- Advanced automation with autosampler and flow cell capabilities
- Optional features including Pulsed-Field Gradients for 2D NMR analysis
The new model, priced between the legacy 60 MHz and 100 MHz versions, targets pharmaceutical, food, chemical, security, advanced materials, mining, and academic sectors. The company will continue offering its original 60 MHz instrument for price-sensitive customers while positioning this new version for industry customers requiring advanced capabilities.
Nanalysis Scientific Corp (OTCQX: NSCIF) has reported strong preliminary Q4 2024 results, with revenue of at least $11 million and record quarterly adjusted EBITDA exceeding $1 million. This represents growth of at least $1.2MM in revenue and $1.8MM in adjusted EBITDA compared to Q4 2023.
The company achieved significant milestones including positive operating and free cash flow in 2024, record sales of 15 100MHz Benchtop NMR units in Q4, and approximately $26 million in security services revenue for 2024. The security services business improved from negative gross margins at the start of 2024 to positive double-digit margins by year-end.
Notable achievements include a co-published study with USP demonstrating Benchtop NMR efficacy for pharmaceutical quality control and two new US patents for NMR magnet and software platform technology. While achieving positive EBITDA and cash flow, after-tax Net Income remained negative for 2024.
Nanalysis Scientific Corp (TSXV: NSCI, OTCQX: NSCIF) and the United States Pharmacopeia (USP) have published a study confirming the effectiveness of benchtop NMR for quality control of active pharmaceutical ingredients. The study highlights benchtop NMR's potential in the multi-billion-dollar pharmaceutical quality control market.
The technology offers several advantages including faster measurements, reduced solvent consumption, simple sample preparation, calibration-free operation, and non-destructive testing. USP's automated analysis method, USP-ID, reduces barriers to entry for benchtop NMR in pharma/biotech QC applications.
The company plans to submit multiple benchtop NMR methods to USP for acceptance, targeting expansion into global pharmacopeia jurisdictions including Europe and Japan.